Legend Biotech Cash Flow Statement
NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.62-0.09 (-0.48%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Legend Biotech free cash flow
In fiscal 2025, Legend Biotech generated -$100.2 million of operating cash flow and spent $28.6 million on capital expenditures. That left free cash flow of -$128.8 million, a free-cash-flow margin of -12.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Legend Biotech cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -296.80M | -177.00M | -518.30M | -446.35M | -403.58M | -266.37M | -101.59M | -2.78M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| Operating Cash Flow | -100.20M | -144.00M | -393.30M | -201.28M | -198.47M | -223.00M | -83.06M | 307.68M |
| Capital Expenditures | -28.60M | -14.10M | -20.10M | -20.93M | -42.20M | -26.25M | -26.77M | -20.96M |
| Investing Cash Flow | 709.60M | -850.60M | 92.90M | -77.09M | -194.98M | -24.17M | -58.65M | -102.26M |
| Debt Issued | — | — | — | — | — | — | 2.87M | — |
| Debt Repaid | — | — | — | — | — | — | -2.87M | — |
| Financing Cash Flow | -300.00K | 5.70M | 791.40M | 377.98M | 626.66M | 618.88M | 14.67M | 2.50M |
| Net Change in Cash | 615.20M | -991.00M | 491.70M | — | — | — | — | — |
| Free Cash Flow | -128.80M | -158.10M | -413.40M | -222.21M | -240.66M | -249.26M | -109.84M | 286.72M |
This table shows 8 annual periods of Legend Biotech's cash flow statement, from FY 2025 back to FY 2018, across 9 line items including net income, operating cash flow, capital expenditures. Values in USD; B = billions, M = millions. Fiscal periods follow LEGN's reporting calendar. What is a cash flow statement?